CA: A Cancer Journal for Clinicians

CA: A Cancer Journal for Clinicians is a medical journal published every two months by Wiley-Blackwell on behalf of the American Cancer Society. This peer-reviewed journal focuses on various elements of cancer research, including diagnosis, treatment, and prevention strategies.

Student/Alumni

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Cytology‐Radiology Correlation Series: Pancreatic cytopathology

1 week ago | acsjournals.onlinelibrary.wiley.com | Judy A. Trieu |Andrew Gilman |Katerina Konstantinoff |Maria Lozano

INTRODUCTION Pancreatic lesions are rising in prevalence, likely because of increasing access to cross-sectional imaging. They can be subtyped into neoplastic and non-neoplastic lesions. Some lesions are characteristic on computed tomography (CT), magnetic resonance imaging (MRI), and/or endoscopic ultrasound (EUS), whereas others are nonspecific.
Natural trajectory subclasses of cognitive impairment in breast cancer patients experiencing insomnia

1 week ago | acsjournals.onlinelibrary.wiley.com | Oxana Palesh |Sarah Braun |Tina Truong |Susan Hong

INTRODUCTION Cancer-related cognitive impairment (CRCI) is a very common adverse effect of cancer and its therapies.1 Cancer itself may negatively impact cognition via vascular and immunological pathways.
A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents

2 weeks ago | acsjournals.onlinelibrary.wiley.com | Daniel Peters |Joshua F. Zeidner

CONFLICT OF INTEREST STATEMENT Joshua F. Zeidner reports consulting or advisory roles for AbbVie, AstraZeneca, Daiichi Sankyo, Foghorn, Genmab, Gilead, Neogenomics, Novartis, Sellas, Servier, Shattuck Labs, Sumitomo Pharma, and Syndax; and research funding from AbbVie, Akesobio, Arog, AstraZeneca, Faron, Gilead, Jazz, Loxo, Merck, Newave, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Pharma, and Zentalis. The other author declares no conflicts of interest.
Shedding LIGHT on the changing landscape of poly‐ADP ribose polymerase inhibitors in ovarian cancer

2 weeks ago | acsjournals.onlinelibrary.wiley.com | Melissa Frey |Joyce Liu

CONFLICT OF INTEREST STATEMENT Joyce F. Liu reports consulting fees from Clovis Oncology, Genentech/Roche, GlaxoSmithKline, Regeneron, AstraZeneca, Eisai, Bristol-Myers Squibb, Daiichi Sankyo, Zentalis, LoxoLilly, and Revolution Medicine. Melisa Frey reports consulting fees from WndrHealth.
Lifetime body weight patterns, weight loss, and renal cell carcinoma subtypes

1 month ago | acsjournals.onlinelibrary.wiley.com | Zhengyi Deng |Chiyuan Zhang |Justin Moore |Saira Khan

CONFLICT OF INTEREST STATEMENT Benjamin I. Chung reports consulting fees from Johnson & Johnson Health Care Systems Inc and VPIX; and travel fees from Intuitive Surgical, Inc. Rebecca E. Graff reports consulting fees from Hunton Andrews Kurth LLP. The other authors disclose no conflicts of interest. Supporting Information Filename Description cncr35763-sup-0001-suppl-data.docx307.8 KB Supplementary Material REFERENCES 1, , , . Cancer statistics, 2023. CA Cancer J Clin.
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer

1 month ago | acsjournals.onlinelibrary.wiley.com | Wataru Fukuokaya |Keiichiro Mori |Takafumi Yanagisawa |Fumihiko Urabe |Pawel Rajwa |Alberto Briganti | +4 more
How an epidemic of untreated malnutrition is worsening cancer

1 month ago | acsjournals.onlinelibrary.wiley.com | Bryn Nelson |William C. Faquin

Physicians have long observed that patients who have cancer and are also malnourished are more likely to die. Beyond making treatments less effective and more toxic, malnutrition can reduce a patient’s functional abilities and quality of life while increasing the risk of complications. For many decades, however, the surprisingly common and largely unresolved phenomenon of malnutrition in patients with cancer was seen as an inevitability.
Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes – A systematic review and meta‐analysis of randomized controlled trials

1 month ago | acsjournals.onlinelibrary.wiley.com | Megan Goh |Marcos Gonzalez |Marcos González |Hillary M. Heiling |Emanuele Mazzola

The role of adjuvant chemotherapy in localized, resectable soft tissue sarcomas (STSs) remains controversial. Despite positive findings reported in previous meta-analyses, the majority of randomized controlled trials (RCTs) fail to show a meaningful benefit.
Estimating cancer incidence attributable to physical inactivity in the United States

2 months ago | acsjournals.onlinelibrary.wiley.com | Brigid Lynch |Julie Bassett |Roger Milne |Alpa Patel

INTRODUCTION Most studies that have estimated the burden of cancer attributable to physical inactivity have been guided by World Cancer Research Fund/American Institute for Cancer Research risk factor grading criteria from their Third Expert Report.1 For example, the Global Burden of Disease 2019 Cancer Risk Factor Collaborators used these criteria, and estimated the cancer disability-adjusted life-years (DALYs) attributable to breast and colorectal cancer around the world.
Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019 - Waks - 2025 - Cancer - Wiley Online Library

2 months ago | acsjournals.onlinelibrary.wiley.com | Adrienne G. Waks |Paolo Tarantino |Emily Chen |Rachel A. Freedman

INTRODUCTION Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15%–20% of invasive breast cancers and is an unfavorable prognostic factor.1 The administration of HER2-directed therapy has transformed outcomes for patients who have HER2-positive breast cancer.